Covid-19 antibody therapies as Omicron and the variant's latest offshoots have likely rendered them obsolete, according to the news agency Reuters.
These two therapies, some of the first medicines developed early in the pandemic, are designed to work by binding to the spike protein of SARS-CoV-2 to neutralize the virus' ability to infect cells.
However, both therapies continue to be recommended for use by the European drugs regulator. Mounting evidence from lab tests suggests that the two therapies (sotrovimab and casirivimab imdevimab) have limited clinical activity against the latest mutations of the virus, as a result, they have fallen out of favor with the US health regulator.
The WHO health experts on Thursday strongly advised the use of the two therapies in patients with Covid-19, reversing previous conditional recommendations endorsing them, as part of a suite of recommendations published in the British Medical Journal.